These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 27849169)

  • 1. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
    Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
    J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.
    VanSeggelen H; Hammill JA; Dvorkin-Gheva A; Tantalo DG; Kwiecien JM; Denisova GF; Rabinovich B; Wan Y; Bramson JL
    Mol Ther; 2015 Oct; 23(10):1600-10. PubMed ID: 26122933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D.
    Wang Z; Guo L; Song Y; Zhang Y; Lin D; Hu B; Mei Y; Sandikin D; Liu H
    Cancer Immunol Immunother; 2017 Apr; 66(4):537-548. PubMed ID: 28184969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
    Barber A; Zhang T; Sentman CL
    J Immunol; 2008 Jan; 180(1):72-8. PubMed ID: 18097006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.
    Barber A; Sentman CL
    J Immunol; 2009 Aug; 183(4):2365-72. PubMed ID: 19625653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
    Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
    Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
    Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
    Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
    Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
    Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
    Front Immunol; 2020; 11():580328. PubMed ID: 33384686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKG2D CARs as cell therapy for cancer.
    Sentman CL; Meehan KR
    Cancer J; 2014; 20(2):156-9. PubMed ID: 24667963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.